Literature DB >> 514315

Role of plasma membrane defect of skeletal muscle in malignant hyperthermia.

E M Gallant, R E Godt, G A Gronert.   

Abstract

Halothane, at clinical concentrations, depolarizes the plasma membrane of skeletal muscle from Poland China pigs susceptible to malignant hyperthermia but does not affect the resting membrane potential of muscle from normal poland China pigs, mice, or frogs. The depolarization is reduced or partially reversed in the presence of dantrolene sodium. We suggest the possibility that malignant hyperthermia may be initiated by this abnormal depolarization of skeletal muscle by halothane.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 514315     DOI: 10.1002/mus.880020610

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Increased membrane fluidity of erythrocytes in a case with malignant hyperthermia.

Authors:  M Kawamoto; K Fujii; H Kikuchi; M Morio
Journal:  J Anesth       Date:  1987-03-01       Impact factor: 2.078

Review 2.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

Review 3.  Malignant hyperthermia: molecular defects in membrane permeability.

Authors:  K S Cheah; A M Cheah
Journal:  Experientia       Date:  1985-05-15

Review 4.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

5.  Membrane abnormality in malignant hyperthermia.

Authors:  A Shah; V Sahgal; V Subramani
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 6.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

7.  Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

Authors:  B A Britt; E Scott; W Frodis; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1984-03

Review 8.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

9.  Canine malignant hyperthermia susceptibility: erythrocytic defects--osmotic fragility, glucose-6-phosphate dehydrogenase deficiency and abnormal Ca2+ homeostasis.

Authors:  P J O'Brien; G W Forsyth; D W Olexson; H S Thatte; P B Addis
Journal:  Can J Comp Med       Date:  1984-10

10.  High skeletal muscle adenylate cyclase in malignant hyperthermia.

Authors:  J H Willner; C G Cerri; D S Wood
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.